What is Viva Biotech Holdings (VBIZF)?

Viva Biotech Holdings (VBIZF) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of VBIZF?

The current price of VBIZF is $0.19. Prices are updated in real time on Stocks360.

What is VBIZF's price-to-earnings (PE) ratio?

VBIZF's trailing twelve-month PE ratio is 12.89, based on current price and earnings per share data available on Stocks360.

What is VBIZF's market capitalization?

VBIZF's market capitalization is $397,682,959.00, placing it in the small-cap tier.

Viva Biotech Holdings (VBIZF)

Stock analysis · OTC · Healthcare · Biotechnology

$0.19

Market Cap

$397.68M

PE (TTM)

12.89

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.38

Day Range

$0.19 – $0.19

52-wk Range

$0.13 – $0.34

Avg Volume

N/A

Volume

5.50K

Viva Biotech Holdings (VBIZF) is a publicly traded company in the Healthcare sector. Latest price: $0.19. Market cap $397.68M. Trailing PE 12.89. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 9 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-31 · $0.30 2026-10-26 · $0.19 (-35.15%)

Earnings

Next Earnings

Apr 1, 2027

EPS estimate $0.00

Proprietary Signals

Signal snapshot temporarily unavailable.

About Viva Biotech Holdings

As an investment holding enterprise, Viva Biotech Holdings provides comprehensive drug discovery services, leveraging a structure-based approach for biotechnology and pharmaceutical clients across the globe. Their offerings encompass discovery biology, including protein expression and purification, structural biology, identification of promising drug candidates (hit discovery), bioassay development, analysis of biomolecular interactions, and pharmacokinetics. They also deliver a range of chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, preparation for purification, and computer-aided drug design (CADD), supported by advanced chemical technology platforms. Furthermore, Viva Biotech excels in antibody drug research and development. These services span from antigen preparation and multi-species discovery to the generation of monoclonal antibodies, functional screening and identification, engineering transformation, characterization, and cell line engineering. They utilize a suite of sophisticated technology platforms for this, including hybridoma, phage, yeast, and mammalian display systems, VHH antibody technology, high-throughput sequencing, comp…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	12.89×
P/S (TTM)	1.16×
P/B	0.56×
PEG	14.99×
P/FCF (TTM)	7.68×
EV / EBITDA	5.22×
EV / Sales	1.08×
Earnings Yield	7.94%
Free Cash Flow Yield	13.02%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$2.05B
Revenue (TTM)	$1.89B
Net Income (TTM)	$173.62M
Free Cash Flow (TTM)	$312.76M
Net Debt	-$137.89M
Working Capital	$614.41M
Gross Margin	34.55%
Operating Margin	10.05%
Net Margin	9.36%
Return on Equity	4.45%
Return on Invested Capital	2.61%